glp 1 ckd renal impairment Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs Proposed algorithm for SGLT2 inhibitor

Ideally incorporate rigorous baseline and follow-up assessments: DEXA, body composition, visceral fat, renal function, endocrine panels, inflammatory biomarkers (IL-6, TNF-, SASP markers if available)

it also has health benefits, not just whitening

Semaglutide 2.4 mg has the most extensive cardiometabolic, renal, and hepatic outcome evidence

The most common time to experience side effects is when you first start taking a GLP-1 or when there is a prescribed increase in your dose

Before giving your child any supplement for weight management or metabolic health, speak with your child's pediatrician or pediatric endocrinologist